Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSELR plus ACEI vs ACEI plus placebo in pediatric IgA nephropathy
ChiCTR2500103806Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of total saponins from rehmannia leaves in IgA nephropathy (IgAN) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Urine protein quantitation at week 12. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
total saponins from rehmannia leaves
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2500103806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103806.